Analysing a pharma product for all possible nitrosamines can involve a long process of method development and validation, particularly in complex matrices with low analytical thresholds. But are there better methods available?
By targeting the most likely occurring nitrosamines for a product by utilising unique chemistry and formulation, may better describe the risk and reduce the complexity and time of laboratory analysis.
